Amendments to the Claims

13. (previously amended) A method of reducing the mortality and morbidity after myocardial infarction, comprising administering to a patient in need thereof, a pharmaceutical composition comprising a compound selected from the group consisting of GLP-1, GLP-1 analogs, and GLP-1 derivatives at a dose effective to normalize blood glucose.

14. (original) A method of reducing the mortality and morbidity after myocardial infarction, comprising administering to a patient in need thereof, a compound selected from the group consisting of GLP-1, GLP-1 analogs, and GLP-1 derivatives, wherein the administration occurs within the first 72 hours following a myocardial infarction.

15. (original) A method of reducing the mortality and morbidity after myocardial infarction, comprising administering to a patient in need thereof, a GLP-1 derivative at a dose effective to normalize blood glucose.

16. (original) The method of Claim 15, wherein the GLP-1 derivative is a GLP-1 analog having an acylated lysine ε-amino group.

17. (original) The method of Claim 13, wherein the compound is complexed with a divalent metal cation.

18. (previously amended) The method of Claim 13, wherein the pharmaceutical composition further comprises a preservative selected from the group consisting of meta-cresol and phenol.

19. (original) The method of Claim 13, wherein the compound is selected from the group consisting of Val8 -GLP-1(7-37), Gly 8 -GLP-1(7-37), GLP-1(7-37), and GLP-1(7-36)NH 2 .

20-21 (canceled)

22. (previously added) The method of Claim 13, wherein the pharmaceutical composition further comprises a buffer.

23. (previously added) The method of claim 13, wherein the composition is administered at a dose effective to target blood glucose levels from about 4.1 mM to 7.5 mM.

24. (previously added) The method of claim 14, wherein the compound is administered at a dose effective to target blood glucose levels from about 4.1 mM to 7.5 mM.

25. (previously added) The method of claim 16, wherein the compound is administered at a dose effective to target blood glucose levels from about 4.1 mM to 7.5 mM.

26. (canceled)